(90 days)
The NxStage System One is indicated for treatment of renal failure or fluid overload using hemofiltration, hemodialysis, and/or ultrafiltration. All treatments must be administered by a health care provider, under physician's prescription.
The NxStage System One consists of the NxStage Cycler and the NxStage Cartridge Extracorporeal Blood and Fluid Circuit. The NxStage Cycler is an electro-mechanical device that interfaces with the NxStage Cartridge. The NxStage Cartridge is a single-use extracorporeal blood circuit and fluid management device that mounts integrally within the NxStage Cycler. The NxStage Cartridge Express is a single-use extracorporeal blood circuit and fluid management device with a pre-attached high flux (permeability) hollowfiber filter.
The provided text describes the NxStage System One with Cartridge Express, a device intended for the treatment of renal failure or fluid overload using hemofiltration, hemodialysis, and/or ultrafiltration. However, the document does not contain the detailed information necessary to complete all sections of the request, particularly regarding specific acceptance criteria, a dedicated study proving performance against those criteria, sample sizes for test and training sets, expert qualifications, or details about comparative effectiveness studies.
Here's a summary of the information that can be extracted and a note on what is missing:
1. Table of Acceptance Criteria and Reported Device Performance
The document does not explicitly state specific numerical acceptance criteria or detail the reported device performance against such criteria. It generally states that "Performance testing was conducted to characterize the performance of the NxStage Cartridge Express during hemodialysis to provide a basis of comparison to the predicate devices. Results of the performance testing have documented that the NxStage Cartridge Express is substantially equivalent to the predicate devices and is suitable for the labeled indication for use."
Therefore, a table cannot be constructed with specific criteria or performance metrics from the provided text.
2. Sample Size Used for the Test Set and Data Provenance
The document mentions "Performance testing" but does not specify the sample size used for any test set or the data provenance (e.g., country of origin, retrospective or prospective nature).
3. Number of Experts Used to Establish the Ground Truth for the Test Set and Their Qualifications
This information is not provided in the document.
4. Adjudication Method for the Test Set
This information is not provided in the document.
5. If a Multi-Reader Multi-Case (MRMC) Comparative Effectiveness Study Was Done, and the Effect Size
The document does not describe a Multi-Reader Multi-Case (MRMC) comparative effectiveness study, nor does it quantify any effect size of human readers improving with or without AI assistance. The device in question is a medical device (dialyzer system), not an AI-assisted diagnostic tool.
6. If a Standalone (i.e., algorithm only without human-in-the-loop performance) Was Done
The device is an electro-mechanical system for treating renal conditions, not an algorithm. Therefore, the concept of "standalone (algorithm only)" performance is not applicable to this device described in the document.
7. The Type of Ground Truth Used
The document indicates that performance testing was conducted to demonstrate "substantial equivalence to the predicate devices" and "suitability for the labeled indication for use." This implies that the "ground truth" or reference for evaluating the device's performance was based on the performance characteristics of its predicate devices, rather than an independent gold standard like pathology or long-term outcomes data, as would be typical for a diagnostic device.
8. The Sample Size for the Training Set
The document does not mention a training set, as the device is not an AI/machine learning model that undergoes a training phase.
9. How the Ground Truth for the Training Set Was Established
As there is no mention of a training set, this information is not applicable or provided.
§ 876.5860 High permeability hemodialysis system.
(a)
Identification. A high permeability hemodialysis system is a device intended for use as an artificial kidney system for the treatment of patients with renal failure, fluid overload, or toxemic conditions by performing such therapies as hemodialysis, hemofiltration, hemoconcentration, and hemodiafiltration. Using a hemodialyzer with a semipermeable membrane that is more permeable to water than the semipermeable membrane of the conventional hemodialysis system (§ 876.5820), the high permeability hemodialysis system removes toxins or excess fluid from the patient's blood using the principles of convection (via a high ultrafiltration rate) and/or diffusion (via a concentration gradient in dialysate). During treatment, blood is circulated from the patient through the hemodialyzer's blood compartment, while the dialysate solution flows countercurrent through the dialysate compartment. In this process, toxins and/or fluid are transferred across the membrane from the blood to the dialysate compartment. The hemodialysis delivery machine controls and monitors the parameters related to this processing, including the rate at which blood and dialysate are pumped through the system, and the rate at which fluid is removed from the patient. The high permeability hemodialysis system consists of the following devices:(1) The hemodialyzer consists of a semipermeable membrane with an in vitro ultrafiltration coefficient (K
uf ) greater than 8 milliliters per hour per conventional millimeter of mercury, as measured with bovine or expired human blood, and is used with either an automated ultrafiltration controller or anther method of ultrafiltration control to prevent fluid imbalance.(2) The hemodialysis delivery machine is similar to the extracorporeal blood system and dialysate delivery system of the hemodialysis system and accessories (§ 876.5820), with the addition of an ultrafiltration controller and mechanisms that monitor and/or control such parameters as fluid balance, dialysate composition, and patient treatment parameters (e.g., blood pressure, hematocrit, urea, etc.).
(3) The high permeability hemodialysis system accessories include, but are not limited to, tubing lines and various treatment related monitors (e.g., dialysate pH, blood pressure, hematocrit, and blood recirculation monitors).
(b)
Classification. Class II. The special controls for this device are FDA's:(1) “Use of International Standard ISO 10993 ‘Biological Evaluation of Medical Device—Part I: Evaluation and Testing,’ ”
(2) “Guidance for the Content of 510(k)s for Conventional and High Permeability Hemodialyzers,”
(3) “Guidance for Industry and CDRH Reviewers on the Content of Premarket Notifications for Hemodialysis Delivery Systems,”
(4) “Guidance for the Content of Premarket Notifications for Water Purification Components and Systems for Hemodialysis,” and
(5) “Guidance for Hemodialyzer Reuse Labeling.”